Lexicon Pharmaceutcl LXRX

$1.82 0.00 (—)

Valuation

Market cap
809,820,000
Revenue TTM
$49,800,000
Net income TTM
$-50,340,000
PE ratio
0.00
Forward PE
—
Profit margin
-101.08%
Debt to equity
0.29

Trading

Volume
2,317,700
Avg volume
2,996,780
Day's range
$1.80 – $1.87
Shares out
444,956,000
Stochastic %K
13%
Beta
1.07
Analysts
Strong Sell
Price target
$4.55

Price

Company profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotaglifloz...

Show more

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Industry
Biotechnology
Sector
Healthcare
Phone
281 863 3000
Website
https://www.lexpharma.com
Address
2445 Technology Forest Boulevard, 11th Floor, The Woodlands, United States

Latest news

Stocktwits

Islandman40 Oct 4, 3:05 AM
$LXRX
0 replies
gucag006 Oct 3, 10:53 PM
$LXRX I really don't have the answers, but asked AI repeatedly, and it told me that if FDA told the company that Stano1 trial's safety & exposure results should be enough to support a Zynquista/T1D resubmission, it most likely will not deploy another AdCom this time. I tend to agree with you, if AdCom were deployed, the case would be dead in the water again. On the approval and revenue potential, there are so much unknowns such as commercial partner or go-to-market by themselves, if the former, Viatris, Novo or others. Until all these become clear, I don't know how to estimate its value to add to the SP.
1 replies
Islandman40 Oct 3, 5:44 AM
$LXRX
0 replies
ChrisBAB Oct 2, 7:46 PM
$LXRX Added more after a successful day trade on another ticker. Loaded with Lexi across three different accounts. Patience will pay off! 💪
0 replies
macrossluvsrobotech Oct 2, 6:17 PM
$LXRX The Amylin Trap vs. Oral ACSL5 Solution 🧬💊 $LLY BE TRYIN ... but $NVO has a secret weapon 😎 = CNBC reports Lilly & Novo are racing into amylin combinations, pushing 23% weight loss—but hitting a wall with up to 27% of patients dropping out from severe nausea/vomiting! Why Lexicon's ACSL5 (partnered with Novo) solves this: 1. Synthetic Overload vs Natural Release: Stacking injectable peptides (EloraTZP/CagriSema) floods brainstem receptors with artificial hormones, requiring multi-billion-dollar cold-chain CapEx. ACSL5 is an oral small molecule acting locally in the gut to trigger the body's natural "ILEAL BRAKE," releasing endogenous GLP-1 & PYY. 2. Slide 10 Proof: Novo confirmed "Improved tolerability vs GLP-1s," zero titration steps, and -33% weight loss combined with sema 3. Bolt-On M&A: Novo needs oral non-incretins to counter Lilly. LXRX’s ~$770M EV is a pure value play. CNBC: https://www.cnbc.com/2026/10/02/lilly-novo-amylin-obesity-drugs.html $NVO $LLY $BIB $VTRS
0 replies
Jas7235355 Oct 2, 6:07 PM
$LXRX Why would Burner keep telling this stuff on this forum? Has he somehow lost a lot of money in the past with LXRX or he just being paid to keep writing all this stuff to keep SP down
2 replies
macrossluvsrobotech Oct 2, 6:05 PM
$LXRX Q4 Intelligence: Sota T1D, Cantor $8 PT & M&A 🏛️🧬 Fresh updates on Lexicon ($LXRX) as Q4 2026 opens: 1. Cantor $8 Price Target: Cantor Fitzgerald initiated coverage with an Overweight rating and an $8.00 target (>340% upside), joining Wall Street Buy upgrades into year-end. 2. Sota T1D Resubmission: Zynquista NDA refiling on track for Q4 2026, backed by STENO-1 real-world safety data. 3. Political Tailwinds: With HHS Secretary RFK Jr. pushing the MAHA chronic disease agenda into the midterms, approving the 1st oral pill to reduce daily insulin injections delivers a major win for chronic illness reform. 4. M&A Heat: Lilly’s $6.5B Houston plant pressures Novo (CMD Slide 13 bolt-on plan) to acquire LXRX (~$770M EV) ahead of Q1 '27 HCM Phase 3 & ACSL5 ). Cantor Note: https://www.marketbeat.com/instant-alerts/analyst-lexicon-pharmaceuticals-nasdaq-lxrx-coverage-initiated-by-analysts-at-cantor-fitzgerald-2026-09-28/ $NVO $LLY $VTRS $BIB
0 replies
Beebomb Oct 2, 5:32 PM
$LXRX I am confused about the prospects for pilavadapin and will appreciate your enlightening comments. My understanding is that the 10 mg dose shows statistically significant pain relief without disqualifying side effects in Phase II. Phase III requires a financial partner but no commitment has been made while the company explores applications beyond DPNP. If this is not the case, let me know what you think is actually happening.
5 replies